Dr. Stefanie Fischer
Medizinische Onkologie und Hämatologie · Dept. I
Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.
Oct 31, 2024
Clinical Studies - Oct 31, 2024 - Dec 31, 2028
Ongoing
Project leader: Fischer Stefanie
Members: Dei Cas Alissa
A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents
Oct 18, 2023
Clinical Studies - Oct 18, 2023 - Dec 31, 2028
Ongoing
Project leader: Fischer Stefanie
Members: Harder Anja, Quinter Janine
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Feb 7, 2023Zweck dieser Studie ist die Bewertung potenzieller neuer Krebstherapien für inoperable, fortgeschrittene oder metastasierte solide Tumore. Die Studie soll Informationen über Sicherheit, Verträglichkeit, die Menge des Arzneimittels bzw. der Arzneimitt...
Clinical Studies - Feb 7, 2023 - Dec 31, 2026
Ongoing
Project leader: Fischer Stefanie
Members: Bürki Ramona, Quinter Janine
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer
Nov 30, 2022Diese Studie wird durchgeführt, um mehr über AMG 509 als Monotherapie (Einzelmedikament) und AMG 509 in Kombination mit Abirateron oder Enzalutamid oder Pemb-rolizumab bei Patienten mit metastasiertem kastrationsre-sistentem Prostatakrebs (mCRPC) zu...
Clinical Studies - Nov 30, 2022 - Dec 31, 2026
Ongoing
Project leader: Fischer Stefanie
Members: Kern Julia, Quinter Janine
Covid 19 Impfantwort, Bedarf und Reaktion auf mögliche Booster- Impfung bei Patienten mit soliden Neoplasien
Oct 1, 2021Patienten mit malignen Erkrankungen stellen eine durch die SARS-CoV-2-Pandemie hoch gefährdete Gruppe dar mit einem hohen Hospitalisations- und Mortalitätsrisiko. Eine Impfung gegen SARS-COV2 stellt neben allgemeinen Schutzmassnahmen das wichtigste E...
Clinical Studies - Oct 1, 2021 - Feb 28, 2021
Automatically Closed
Project leader: Fischer Stefanie
Members: Silzle Tobias, Demmer-Steingruber Ruth, Albrich Werner, Kahlert Christian
SAKK 67/20 Open-label single-stage phase 1B study of the new micellar docetaxel compound Docecal in patients with advanced castra-tion-resistant prostate cancer
May 28, 2021Background: Docetaxel, a semi-synthetic analogue of paclitaxel, is one of the most widely used human anti-cancer agents. Docetaxel and paclitaxel belong to a group of cytotoxic agents called tax-anes. Docetaxel has been marketed worldwide by Sanofi-...
Clinical Studies - May 28, 2021 - Dec 31, 2024
Completed
Project leader: Fischer Stefanie
Members: Aeschbacher Anette
Response to COVID-19 vaccination and COVID-19 infections after vaccination in patients with haematological malignancies
May 1, 2021The prevalence and mortality of COVID-19 are higher in patients with haematological malignancies (HM) compared to the general population (Vijenthira et al. 2020). Two SARS-CoV-2 messenger RNA (mRNA) vaccines have been approved by Swissmedic, both are...
Clinical Studies - May 1, 2021 - Oct 1, 2022
Completed
Project leader: Silzle Tobias
Members: Fischer Stefanie, Kahlert Christian, Albrich Werner
MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
Mar 17, 2021The rationale for this study comes from preclinical models, in which lenvatinib decreased the tumor-associated macrophage (TAM) population, which is known as an immune-regulator in the tumor microenvironment. The decrease in TAM population was accomp...
Clinical Studies - Mar 17, 2021 - May 7, 2030
Ongoing
Project leader: Fischer Stefanie
Members: Donno Monica, Quinter Janine
A Phase II, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Neoadjuvant And Adjuvant Tiragolumab Plus Atezolizumab, With Or Without Platinum-Based Chemotherapy, In Patients With Previously Untreated Locally Advanced Resectable Stage II, IIa, Or Select IIIb Non-Small Cell Lung Cancer
Feb 12, 2021Das Ziel dieser Studie ist es die Wirkungen, ob positiv oder negativ, von Tecentriq (Atezolizumab) und Tiragolumab mit oder ohne Chemotherapie bei Patienten, deren Lungenkrebs operiert werden kann, zu beurteilen. Es soll herausgefunden werden, ob und...
Clinical Studies - Feb 12, 2021 - Jul 24, 2024
Aborted
Project leader: Fischer Stefanie
Members: Sennhauser Andrina, Quinter Janine
A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS
Jul 17, 2020Multizentrische Studie bei Patienten mit metastasiertem Nierenzellkarzinom nach Progredienz unter einer Erstli-nientherapie mit ICI/ICI oder ICI/TKI Kombination zur Eva-luation der Wirksamkeit und Verträglichkeit des Tyrosin-kinase Inhibitors Cabozan...
Clinical Studies - Jul 17, 2020 - Jul 17, 2022
Automatically Closed
Project leader: Rothermundt Christian
Members: Aeppli Stefanie, Fischer Stefanie, Omlin Aurelius
SAKK 01/18 Reduced intensity radio-chemotherapy for satge IIA/B seminoma. A multicenter, open label phase II trial with 2 cohorts
Jul 24, 2019Main objective: To investigate efficacy of a stage-adapted tratment regimen in stage IIA/B seminoma based on the preliminary experience gained in SAKK 01/10. The Goal is to further safely de-escalate Treatment while maintaining / enhancing efficacy.
Clinical Studies - Jul 24, 2019 - Jul 24, 2030
Ongoing
Project leader: Putora Paul Martin
Members: Plasswilm Ludwig, Rothermundt Christian, Patzl Sigrid, Fischer Stefanie
Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial
Oct 15, 2015Der Behandlungsansatz beim FL sah bislang entweder ein zunächst abwartendes Beobachten beim asymptomati-schen Patienten oder aber monotherapeutische Behand-lungen vor, mit dem Ziel, möglichst lange eine gute Le-bensqualität zu erhalten. Für die asymp...
Clinical Studies - Oct 15, 2015 - Dec 31, 2029
Ongoing
Project leader: Hitz Felicitas
Members: Silzle Tobias, Fehr Martin, Fischer Stefanie
An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors
Jul 8, 2015MO29518 ist eine offene, multizentrische, multinationale Phase-II-Studie mit 10 Kohorten, welche MPDL3280A (Anti-PD-L1 Antikörper) bei Patienten mit fortgeschrittenen soliden Tumoren untersucht (Gebärmutterhalskrebs, Nasen-Rachenkrebs, spezielle Art...
Clinical Studies - Jul 8, 2015 - Jul 31, 2019
Automatically Closed
Project leader: Gillessen Sommer Silke
Members: Schmid Sabine, Fischer Stefanie, Rothermundt Christian, Templeton Arnoud, Omlin Aurelius, Desax Marie-Claire, Früh Martin, Weisshaupt Christian
Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)
Jul 7, 2014Background: Denosumab, a monoclonal antibody against RANK-Ligand has been shown to be superior to zoledronic acid in delaying time to a first on-study skeletal-related event (SRE) in patients with solid tumors, with no effects on disease progression...
Clinical Studies - Jul 7, 2014 - Dec 31, 2026
Ongoing
Project leader: Fischer Stefanie
Members: Sakic Miranda, Quinter Janine